Botanix Pharmaceuticals Limited (ASX:BOT) Insider Buys A$3,680,000.00 in Stock

Botanix Pharmaceuticals Limited (ASX:BOT) insider Vince Ippolito bought 8,000,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The stock was purchased at an average cost of A$0.46 ($0.29) per share, with a total value of A$3,680,000.00 ($2,285,714.29).

Botanix Pharmaceuticals Price Performance

The company has a quick ratio of 1.26, a current ratio of 22.21 and a debt-to-equity ratio of 0.19.

Botanix Pharmaceuticals Company Profile

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.